Trend Report
Why Pharma Should be Focusing on ESG
A comprehensive look at the environmental, social, and governance imperatives reshaping the pharmaceutical supply chain — and how Datwyler is leading by example.
Status
Published
Format
Trend Report
Language
English
Access
Registration Required
Resource Overview
About this Trend Report
The pharmaceutical industry's ESG obligations extend far beyond emissions reduction — encompassing supply chain transparency, health equity, data governance, and ethical business practices. This 2022 report by Datwyler examines the three interconnected pillars of ESG — environmental, social, and governance — and makes the case for why pharma companies and their packaging partners must treat sustainability as a strategic priority, not a compliance exercise.
On the environmental front, the report cites research showing pharma's emission intensity is approximately 55% higher than the automotive industry, and spotlights actionable steps including green facility design, electric vehicle fleets, and the elimination of single-use plastics.
On the social side, it addresses health and safety obligations, human rights in the supply chain, diversity in clinical trials, and community healthcare access.
Governance coverage includes regulatory compliance, anti-corruption measures, and ethics as a long-term business driver. As a founding member of Alliance to Zero — a pharma supply chain initiative targeting net zero emissions by 2030 — Datwyler details its own measurable sustainability progress: renewable electricity doubled to 38% of total consumption, CO₂ emissions per revenue unit reduced by 8.1% four years running, a 74.1% waste recycling rate, and ecodesign innovations like DuraCoat™ and a Pune solar plant.
The report positions collaborative supply chain action as the only path to meaningful, industry-wide ESG transformation.
Access This Resource
Download the Trend Report
Continue to access the full resource.
Read the Report
Quick access in under 30 seconds.
